A new drug called Letairis (ambrisentan) plus new guidelines are updating treatment for pulmonary arterial hypertension

Please see the August 2012 FDA warning concerning the use of Revatio in children with PAH

A new drug called Letairis (ambrisentan) plus new guidelines are updating treatment for pulmonary arterial hypertension.

In pulmonary arterial hypertension, there is continuous high blood pressure in the pulmonary arteries...which carry oxygen-poor blood from the right ventricle to the lungs.

It's a rare condition that's due to tightening of pulmonary arteries...thickening of the walls of pulmonary arteries...or to blockages caused by blood clots in smaller arteries.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote